Rakova announced clinical trials of a vaccine against a new strain of COVID-19

Clinical studies of the Sputnik-V and single-component Sputnik Light vaccines, adapted for the new strain of CORONAVIRUS XBB-1, have begun in the capital’s medical institutions . This was announced by Deputy Mayor of Moscow for Social Development Anastasia Rakova.

“Moscow was the first to launch a clinical trial of a vaccine against covid-19 in 2020. And today, together with the Institute named after N.F. In Gamaleya, we are the first to begin research on already proven drugs adapted for the new strain of coronavirus infection XBB-1,” the vice mayor emphasized.

Clinical studies are carried out on the basis of three institutions - First Moscow State Medical University named after. THEM. Sechenov and two city clinics. Thus, on the basis of branch No. 3 of city clinic No. 64 (Izmailovo district) the one-component vaccine “Sputnik Light” is being studied, and on the basis of branch No. 5 of city clinic No. 62 (Airport district) - the two-component “Sputnik-V”.

According to Rakova, each of the studies will take 90 days and will require the involvement of 50 volunteers, the recruitment of which has already been completed. “At the end of the research, we plan to purchase new drugs so that all residents of the capital can receive reliable protection against the current strain of coronavirus infection,” the deputy mayor added.

The clinical research ecosystem created in the capital includes centers based in clinics and hospitals, city laboratories and specialized institutions. All of them are connected by a single digital circuit, which ensures quality, reliability and speed of research. Thus, in 2020, based on the ecosystem, in less than four months it was possible to conduct a study of the Sputnik-V vaccine with the participation of 22 research centers and the involvement of 33 thousand volunteers.